Date posted: 4/13/2012
An additional warning has been issued over the safety of Actos by Canada’s top drug regulatory agency.
Health Canada announced on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. The agency will also require a change to warning labels of the drug to address the risk.
Health Canada functions in a similar role as that of the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.
After the June 2011 FDA warning, the Canadian agency launched a study which found users of Actos are more than 40% more likely to develop bladder cancer.
The news caps off a 12-month period of terrible news for Actos and its’ users. Last year, regulators in Germany and France banned Actos after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.
In the United States, Takeda Pharmaceuticals faces as many as 10,000 Actos lawsuits from patients alleging that they suffered Actos bladder cancer. The cases have been consolidated to a federal multi-district litigation court in Louisiana.
Anyone who has taken Actos is urged to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer should contact a lawyer about their legal options.
Due to the large amount of cases likely to be litigated, anyone affected should make sure they choose a lawyer very qualified for defective drug litigation, the MDL process and Actos lawsuits.
The Actos Bladder Cancer Center only works with the top defective drug lawyers and law firms for Actos cases.